GRACE :: Kidney Cancer

PD-1

GRACE Video

Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?

Share

Cancer Grace ASCO 2015 - Video 02-HD

 

Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 


GRACE Video

Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival

Share

Cancer Grace ASCO 2015 - Video 01-HD

 

The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 


GRACE Video

Kidney Cancer Immunotherapy: Reasons for Cautious Optimism

Share

Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments.


GRACE Video

Kidney Cancer Immunotherapy: PD-1 Pathway Clinical Trials

Share

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.


PD-1 Inhibitors for Kidney Cancer

Share

I wanted to update the audience at Cancer GRACE with some really interesting developments at the American Society of Clinical Oncology meeting this year. Dr Charles Drake, from Johns Hopkins University, presented data related to the agent nivolumab, a so-called PD-1 inhibitor. I’m quite sure that PD-1 inhibitors are going to be drugs you’ll be hearing a lot about in coming years, along with PD-L1 inhibitors. These are drugs that work at the interface between immune-based cells called T-cells as well the cancer cell. Essentially, what they do is they stimulate the body’s own immune response to fight cancer.

There’s been a lot of talk related to some data from a Phase I clinical trial of nivolumab that encompasses a number of cancer types, including lung cancer and melanoma, as well as patients with kidney cancer. I wanted to mention specifically the data related to kidney cancer that has been presented to date. Specifically, Dr. Drake reported results from a total of 34 patients that were treated one of two doses of nivolumab, either 1 mg/kg or 10 mg/kg. In this total cohort of 34 patients, it was noted that 29% of patients had responses. The median delay in cancer progression, also known as progression-free survival, was 7.3 months. Now this in and of itself might not seem shocking, but what I will say is that patients in this trial were very heavily pre-treated. About half of patients in this study had 3 or more prior therapies. In my experience, it is relatively rare to see patients who have had this extent of prior therapy respond so well. What might be even more impressive than the response data or the delay in cancer progression is the survival data. That, so far, indicates that about 70% of patients on the trial lived to 1 year, and about half of patients are still alive at 2 years and beyond.

Continue reading


Ask Us, Q&A
Kidney Cancer Expert Content

Archives

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243